Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Simnotrelvir + ritonavir - Simcere Pharmaceutical Group

Drug Profile

Simnotrelvir + ritonavir - Simcere Pharmaceutical Group

Alternative Names: Anti-COVID 19 oral 3CL inhibitor; Anti-COVID-19 3CL inhibitor; SD-8432; SIM-0417; Simnotrelvir; Simnotrelvir/ritonavir tablets (co-packaged); SSD-8432; XIANNUOXIN

Latest Information Update: 27 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Institute of Materia Medica
  • Developer Simcere Pharmaceutical Group
  • Class Amides; Antivirals; Carbamates; Small molecules; Thiazoles
  • Mechanism of Action Coronavirus-3C-like-proteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed COVID 2019 infections

Most Recent Events

  • 27 Apr 2023 Simcere Pharmaceutical initiates a phase I pharmacokinetic trial (In volunteers, In the elderly) in China (PO) (NCT05826249)
  • 21 Mar 2023 Jiangsu Simcere Pharmaceutical completes a phase II/III trial for Covid-2019 infections in China (PO) (NCT05506176)
  • 26 Feb 2023 Launched for COVID-2019 infections in China (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top